The global Clindamycin phosphate injection market is estimated to grow at a significant CAGR during the forecast period. Clindamycin injection is used to treat bacterial infections of the lungs, bones, joints, skin, blood, internal organs and female reproductive organs. Clindamycin belongs to a class of medications known as lincomycin antibiotics.
Clindamycin is derived from lincomycin it’s naturally occurring lincosamide and an eponymous, it is an antibiotic class and it has superior properties over the parent compound. Due to its superior property, it is largely replaced. The US Food and Drug Administration (FDA) has approved the clindamycin drug for the treatment of skin structure infection, intra-abdominal, gynaecological, bone and joint infection, lower respiratory. Clindamycin is also prescribed for the treatment of acne vulgaris, streptococcal pharyngitis, severe pelvic inflammatory disease and bacterial vaginosis. For the treatment of aspiration pneumonia and community-acquired pneumonia using intravenous (IV), The Infectious disease society of America has published the guidelines for clindamycin drugs.
A full report of Clindamycin Phosphate Injection Market is available at: https://www.omrglobal.com/industry-reports/clindamycin-phosphate-injection-market
Clindamycin is used by dentists as a prophylactic coverage against endocarditis. Clindamycin injection is also often used to treat malaria. Due to low immune systems in adults and in unborn babies whose mothers are infected may have a serious problem due to the infection such as anthrax and toxoplasmosis, clindamycin injection is used to treat this infectious disease. In some pregnant women, Clindamycin injection is also used to prevent the baby’s infection during childbirth.
Some of the key players contributing to the growth of the market include Pfizer inc., Akorn inc., Almaject inc., Baxter International Inc., and Sagent pharmaceuticals., among others. For instance, in August 2021 Sagent pharmaceuticals released a back-order of 150 mg/mL 60 mL of clindamycin phosphate. Furthermore, Pfizer has a back-order vials Cleocin 150 mg/mL 4 mL that is estimated by the Company to be released in February 2022.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/clindamycin-phosphate-injection-market
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segments Covered
o By Types
o By Application
- Regions Covered
o North America
o Europe
o Asia-Pacific
o Rest of the world
- Competitive Landscape- Pfizer inc., Akorn inc., Almaject inc., Baxter International Inc., and Sagent pharmaceuticals., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Clindamycin Phosphate Injection Market by Segments
By Types
- 150mg/ml
- 300mg/50ml
- 600mg/50ml
- 900mg/50ml
By Applications
- Hospital
- Clinics
- Recovery Center
Company Profiles
- Pfizer inc.
- Akorn inc.
- Almaject inc.
- Baxter International Inc.
- Sagent pharmaceuticals
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
